The handout describes the main characteristics of LTBI and Active TB, as well as their differences. The material also describes what increases the risk for developing Active TB and how to prevent TB from developing. English is on one side and Mandarin is on the other.
This material was developed for clinicians to use with patients that are prescribed the four months daily rifampin (4R) regimen for the treatment of latent TB infection. There is space to write treatment information, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 4R regimen.
This material was developed for clinicians to use with patients that are prescribed the 12-dose regimen for the treatment of latent TB infection. There is space to write treatment schedules, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 12-dose regimen.
Infographic for New York City citizens on how to stop TB.
Today, TB Alliance held a virtual meeting of its Stakeholders Association and other tuberculosis (TB) and global health stakeholders around the world to highlight the recent rapid communication issued by the World Health Organization (WHO) Global Tuberculosis Programme regarding updated guidelines for treating drug-resistant tuberculosis (DR-TB) and their potential impact on DR-TB therapy.
Since January of 2016, we have seen an increase of multidrug-resistance tuberculosis (MDR TB) in Minnesota. The severe increase in these rates is due to an MDR TB outbreak within the Hmong community of the east metro. What is very concerning about this outbreak is that it is not regular TB, but MDR TB. This means some of the typical medicines used to treat TB do not work, and we need to use stronger medications over a long period of time to get rid of the disease.
Infographic: Refer clients with symptoms lasting more than 2-3 weeks to a medical provider immediately. Clients with infectious TB disease should not be in group settings.
The American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America jointly sponsored this new practice guideline on the treatment of drug-resistant tuberculosis (DR-TB). The document includes recommendations on the treatment of multidrug-resistant TB (MDR-TB) as well as isoniazid-resistant but rifampin-susceptible TB.
This document provides specific guidance for screening and post- screening management of all people who have been identified through public health investigations as having been exposed to multidrug resistant tuberculosis (MDR TB). Recommendations for symptomatic contacts, children less than 5 years of age and those who are highly immunocompromised (see step 1B) are different from other groups.
This material was developed for clinicians to use with patients that are prescribed the three months of daily isoniazid plus rifampin (3HR) regimen for the treatment of latent TB infection. There is space to write treatment information, medication intake, and doctor/clinic contact information. There is also a checklist of signs and symptoms that may develop while using the 3HR regimen.
